Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis

Pediatric Nephrology

Volumn 20, Issue 5, 2005, Pages 622-630

  Greenbaum, Larry A ^a   Grenda, Ryszard ^b   Qiu, Ping ^c   Restaino, Irene ^d   Wojtak, Amy ^c   Paredes, Ana ^e   Benador, Nadine ^f   Melnick, Joel Z ^c   Williams, Laura A ^c   Salusky, Isidro B ^g  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^c ABBOTT LABORATORIES   (United States)

^d CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^e MIAMI CHILDREN'S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium; End stage renal disease; Phosphorus; Renal osteodystrophy; Secondary hyperparathyroidism

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; PLACEBO; ACETIC ACID DERIVATIVE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT;

ADOLESCENT; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASTHMA; BLOOD TOXICITY; BOLUS INJECTION; CALCIUM BLOOD LEVEL; CARDIOTOXICITY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEADACHE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; INFECTION; KIDNEY FAILURE; LUNG TOXICITY; MALE; NEUROTOXICITY; PAIN; PARATHYROID DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PATIENT MONITORING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RHINITIS; SECONDARY HYPERPARATHYROIDISM; BLOOD; CHRONIC KIDNEY FAILURE; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RENAL OSTEODYSTROPHY; RENAL REPLACEMENT THERAPY;

ACETATES; ADOLESCENT; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CALCIUM CHANNEL AGONISTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; PHOSPHATES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 21244475660     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-004-1792-6     Document Type: Article

References (34)

1. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67:876-881
2. Slatopolsky E, Robson AM, Elkan I, Bricker NS (1968) Control of phosphate excretion in uremic man. J Clin Invest 47:1865-1874
3. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM (1986) Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 78:1296-1301 1:CAS:528:DyaL28XmtF2gtbk%3D
4. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M (1996) Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11:970-976
5. Mathias R, Salusky I, Harman W, Paredes A, Emans J, Segre G, Goodman W (1993) Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. J Am Soc Nephrol 3:1938-1946
6. Salusky IB (1995) Bone and mineral metabolism in childhood end-stage renal disease. Pediatr Clin North Am 42:1531-1550
7. Bulla M, Delling G, Offermann G, Ziegler R, Benz G, Luhmann H, Sanchez de Reutter A, Severin M (1979) Renal bone disorders in children: Therapy with vitamin D3 or 1,25-dihydroxycholecalciferol. Proc Eur Dialysis Transplant Assoc 16:644-648
8. Chesney RW, Moorthy AV, Eisman JA, Jax DK, Mazess RB, DeLuca HF (1978) Increased growth after long-term oral 1alpha,25-vitamin D3 in childhood renal osteodystrophy. N Engl J Med 298:238-242
9. Pierides AM, Ellis HA, Simpson W, Cook D, Kerr DN (1977) The effect of 1alpha-hydroxyvitamin D3 in pre-dialysis renal bone disease. Clin Endocrinol (Oxf) 7:109s-116s
10. Postlethwaite RJ, Houston IB (1977) Bone disease in children with chronic renal failure: Therapy with 1alpha-hydroxyvitamin D3. Clin Endocrinol (Oxf) 7:117s-124s
11. Ramirez JA, Goodman WG, Belin TR, Gales B, Segre GV, Salusky IB (1994) Calcitriol therapy and calcium-regulated PTH secretion in patients with secondary hyperparathyroidism. Am J Physiol 267:E961-E967
12. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 74:2136-2143 6549016
13. Slatopolsky E, Delmez JA (1994) Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 23:229-236
14. Huraib S, Abu-Aisha H, Abed J, Al Wakeel J, Al Desouki M, Memon N (1997) Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidism, parathyroid gland mass and bone mineral density in haemodialysis patients. Am J Nephrol 17:118-123
15. Ettenger RB, Rosenthal JT, Marik JL, Malekzadeh M, Forsythe SB, Kamil ES, Salusky IB, Fine RN (1991) Improved cadaveric renal transplant outcome in children. Pediatr Nephrol 5:137-142
16. Fennell RS, Tucker C, Pedersen T (2001) Demographic and medical predictors of medication compliance among ethnically different pediatric renal transplant patients. Pediatr Transplant 5:343-348
17. Ardissino G, Schmitt CP, Bianchi ML, Dacco V, Claris-Appiani A, Mehls O (2000) No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Kidney Int 58:981-988
18. Ho M, Stablein DM (2002) North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) Annual Report. Rockville, Maryland
19. Nussbaum SR, Zahradnik RJ, Lavigne JR, Brennan GL, Nozawa-Ung K, Kim LY, Keutmann HT, Wang CA, Potts JT Jr, Segre GV (1987) Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 33:1364-1367 1:CAS:528:DyaL2sXkvFSitbc%3D
20. Martin KJ, Gonzalez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 9:1427-1432
21. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166
22. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int 54:907-914 10.1046/j.1523-1755.1998.00045.x
23. Schmitt CP, Huber D, Mehls O, Maiwald J, Stein G, Veldhuis JD, Ritz E, Schaefer F (1998) Altered instantaneous and calcium-modulated oscillatory PTH secretion patterns in patients with secondary hyperparathyroidism. J Am Soc Nephrol 9:1832-1844
24. Gonzalez EA, Martin KJ (1996) Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int 50:63-70
25. Lopez H, Dusso AS, Rapp NS, Martin KJ, Slatopolsky E (1990) Phosphorus restriction reverses hyperparathyroidism in uremia independent of changes in calcium and calcitriol. Am J Physiol 259:F432-F437
26. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F (1991) The effect of long-term intravenous calcitriol administration on parathyroid function in hemodialysis patients. J Am Soc Nephrol 2:1014-1020
27. Brickman AS, Hartenbower DL, Norman AW, Coburn JW (1977) Actions of 1 alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 on mineral metabolism in man. I. Effects on net absorption of phosphorus. Am J Clin Nutr 30:1064-1069
28. Frazao JM, Elangovan L, Maung HM, Chesney RW, Acchiardo SR, Bower JD, Kelley BJ, Rodriguez HJ, Norris KC, Robertson JA, Levine BS, Goodman WG, Gentile D, Mazess RB, Kyllo DM, Douglass LL, Bishop CW, Coburn JW (2000) Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism. Am J Kidney Dis 36:550-561
29. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483-1490
30. Goodman WG (2002) Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. Nephrol Dial Transplant 17:204-207
31. Chang W, Tu C, Bajra R, Komuves L, Miller S, Strewler G, Shoback D (1999) Calcium sensing in cultured chondrogenic RCJ3.1C5.18 cells. Endocrinology 140:1911-1919
32. Chang W, Tu C, Pratt S, Chen TH, Shoback D (2002) Extracellular Ca(2+)-sensing receptors modulate matrix production and mineralization in chondrogenic RCJ3.1C5.18 cells. Endocrinology 143:1467-1474
33. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483
34. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245-252 10.1046/j.1523-1755.2002.00434.x